
MVA-member, 2cureX, and MVA-member, Scandion Oncology, have just announced a new partnership with Erasmus Medical Centre, Rotterdam and received a grant of 800.000 EUR from Eurostars, which will be used to study if Scandion Oncology’s drug candidate, SCO -101 can overcome resistance to antiestrogen therapy in metastatic breast cancer patients, and if 2cureX’s IndiTreast test can stratify such patients based on SCO-101 sensitivity.
Read full press release here